TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia

MLA

Claudia Pérez Carretero, et al. “TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia.” Blood, vol. 140, Nov. 2022, pp. 4105–06. EBSCOhost, https://doi.org/10.1182/blood-2022-168861.

APA

Claudia Pérez Carretero, Miguel Quijada Álamo, Mariana Tannoury, Léa Dehgane, David J. Sanz, Teresa González, Rocio Benito, Elise Chapiro, Maria Hernandez-Sanchez, Ana E. Rodriguez, Florence Nguyen Khac, Santos A. Susin, & Jesús María Hernández-Rivas. (2022). TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia. Blood, 140, 4105–4106. https://doi.org/10.1182/blood-2022-168861

Chicago

Claudia Pérez Carretero, Miguel Quijada Álamo, Mariana Tannoury, Léa Dehgane, David J. Sanz, Teresa González, Rocio Benito, et al. 2022. “TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia.” Blood 140 (November): 4105–6. doi:10.1182/blood-2022-168861.